期刊
IMMUNOBIOLOGY
卷 217, 期 11, 页码 1034-1046出版社
ELSEVIER GMBH
DOI: 10.1016/j.imbio.2012.07.021
关键词
Complement; Complotype; Inflammation; Alternative pathway; Disease; Mutation; Polymorphism
类别
资金
- Wellcome Trust [068823]
- MRC [G0701298]
- Spanish Ministerio de Economia y Competitiviad [SAF2010-26583]
- Communidad de Madrid [S2010/BMD-2316]
- Fundacion Renal Inigo Alvarez de Toledo
- MRC [G0701298] Funding Source: UKRI
- Medical Research Council [G0701298] Funding Source: researchfish
During the last decade, numerous studies have associated genetic variations in complement components and regulators with a number of chronic and infectious diseases. The functional characterization of these complement protein variants, in addition to recent structural advances in understanding of the assembly, activation and regulation of the AP C3 convertase, have provided important insights into the pathogenic mechanisms involved in some of these complement related disorders. This knowledge has identified potential targets for complement inhibitory therapies which are demonstrating efficacy and generating considerable expectation in changing the natural history of these diseases. Comprehensive understanding of the genetic and non-genetic risk factors contributing to these disorders will also result in targeting of the right patient groups in a stratified medicine approach through better diagnostics and individually tailored treatments, thereby improving management of patients. Crown Copyright (C) 2012 Published by Elsevier GmbH. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据